Published in:
01-12-2015 | Letter
Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?
Authors:
Patrick M Honore, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Viola Van Gorp, Herbert D Spapen
Published in:
Critical Care
|
Issue 1/2015
Login to get access
Excerpt
Voriconazole is a first-line agent for treatment of systemic mycotic infections. However, intravenous use is contraindicated in patients with creatinine clearance <50 ml/minute because of accumulation of the toxic vehicle sulfobutylether-beta-cyclodextrin sodium [
1,
2]. In a recent issue of
Critical Care, Kiser and colleagues furnished convincing pharmacological evidence that sulfobutylether-beta-cyclodextrin sodium but not voriconazole was effectively removed by continuous veno-venous hemofiltration (CVVH). They concluded that standard intravenous voriconazole doses could be safely used when patients were placed under continuous renal replacement therapy [
3]. …
